Recently, the group of Clarke showed that a novel stroke therapy agent, perlecan domain V, promotes angiogenesis in brain endothelial cells, by inducing expression and secretion of VEGF via phosphorylation of the ERK1/2 pathway[16]. This evidence concerns the gene MAPK3 and Stroke.